Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**AdimFlu-S Vaccine 2010-2011** was Adimmune's seasonal 2010–2011 **trivalent, inactivated split-virion influenza vaccine**. It was designed to induce hemagglutination-inhibiting antibodies against the three influenza strains included in that season's formulation, covering influenza A H1N1, influenza A H3N2, and influenza B viruses. It was evaluated in Taiwan in infants, children, adolescents, non-elderly adults, and elderly adults, including studies of immunogenicity and safety following intramuscular vaccination. This exact product is distinct from Adimmune's 2009 monovalent pandemic A H1N1 AdimFlu-S vaccine. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01355172))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AdimFlu-S Vaccine 2010-2011.